The main objective of this research was to define the association between common mitochondrial DNA (mtDNA) polymorphisms and mitochondrial transcription A gene (TFAM) variants and myocardial infarction (MI) in patients with atherosclerotic diseased vessels. Ten mitochondrial polymorphisms that defined the nine common European haplogroups were genotyped in 500 male patients with early onset MI (<55 years) and at least one atherosclerotic coronary vessel (angiographically confirmed), and 500 healthy controls. In addition, we searched for DNA variants in the coding region of the TFAM gene and compared patients and controls for the allele and genotype frequencies.
Abstract
The main objective of this research was to define the association between common mitochondrial DNA (mtDNA) polymorphisms and mitochondrial transcription A gene (TFAM) variants and myocardial infarction (MI) in patients with atherosclerotic diseased vessels. Ten mitochondrial polymorphisms that defined the nine common European haplogroups were genotyped in 500 male patients with early onset MI (<55 years) and at least one atherosclerotic coronary vessel (angiographically confirmed), and 500 healthy controls. In addition, we searched for DNA variants in the coding region of the TFAM gene and compared patients and controls for the allele and genotype frequencies.
Early onset MI was strongly associated with male gender and tobacco smoking in our population. MtDNA haplogroup H (defined by allele 7028 C) was significantly more frequent in a first group of patients (n=250) compared to controls (n=300), and the association was confirmed in a second group of only smokers (250 patients and 200 controls). For total patients and controls, we obtained a p=0.002 (OR=1.50; 95% CI= 1.17-1.92) for H vs. the other haplogroups. We found four common TFAM polymorphisms, with allele/genotype frequencies that did not differ between patients and controls.
In conclusion, mitochondrial haplogroup H was associated with early onset MI in male smokers. Our work supported a role for the mtDNA variation in the risk for atherosclerosis and ischemic associated events, likely due to differences in mitochondrial function and reactive oxygen production between the different haplogroups.
Introduction
Mitochondria are the cellular organelles where energy is produced in the form of ATP. As a result of this process reactive oxygen species (ROS) are produced, and these ROS need to be neutralized to avoid extensive cellular damage and senescence. Increased mitochondrial ROS production has been linked to vascular smooth muscle cells (VSMCs) dysfunction, rendering an endothelium vulnerable to the development of atherosclerotic lesions and plaque rupture. A number of cardiovascular risk factors would induce the overproduction of ROS, contributing to the atherosclerotic process. In the last years, several works explained the pro-atherogenic effect of the main cardiovascular risk factors (hyperglycemia, dyslipemia, cigarrette smoking) in terms of mitochondrial dysfunction (Ross 1995; Ballinger et al., 2002; Sorescu et al., 2002; Madamanchi et al., 2007) .
Mitochondria contain their own DNA (mtDNA) in a single circular chromosome and their own transcription and translation machinery. The mtDNA is inherited from the mother and contains the genes for 13 units of the electron transfer chain, 22 tRNAs, and 2 rRNAs. More than 75 human diseases have been associated with rare mutatitons in the mitochondrial genome (DiMauro et al., 2003) . In addition, the mtDNA sequence is highly polymorphic and this variation accumulated sequentially along female lineages. Nine haplogroups defined by mtDNA single nucleotide polymorphisms (SNPs) are commonly used to classify the individuals of European ancestry (Torroni et al., 1996; Ruiz-Pesini et al., 2004; Booker et al., 2006) . These haplogroups have been associated with the risk of developing common diseases, such as Parkinson´s and Alzheimer´s disease, ischemic stroke, coronary artery disease, cardiac hypertrophy, and several types of cancer (van der Walt et al., 2003; van der Walt et al., 2004; Gaweda-Walerych et al., 2008) . These effects on disease susceptibility could be explained by differences between the haplogroups on the efficiency of oxygen consumption and ATP and ROS production (Ruiz-Pesini et al., 2000; Castro et al., 2006; Kofler et al., 2009; MartinezRedondo et al., 2010) .
The mitochondrial transcription factor A (encoded by a nuclear gene, TFAM) plays a major role in mtDNA copy number and transcription (Larsson et al., 1998; Kang et al., 2007) . The number of copies of mtDNA is directly dependent on the levels of mtTFA, with mice heterozygous for a tfam deletion showing a significant reduction in mtDNA copies (Ekstrand et al., 2004) . MtDNA transcripts were upregulated in VSMCs from rats exposed to cigarette smoke, that showed a 4 phenotype characteristic of experimentally induced atherogenesis (Masayesva et al., 2006) .
Conditional heart deletion of tfam reproduced in mice the pathophysiological features of mitochondrial cardiomyopathy, with a significant reduction of mtDNA copies in cardiomyocytes and a reduction in respitarory chain activity (Wang et al., 1999; Li et al., 2000; Kanazawa et al., 2002) . Overexpression of tfam ameliorated mitochondrial deficiencies in postinfarction mice, inhibiting left ventricular remodeling (Russell et al., 2004; Ikeuchi et al., 2005) .
We hypothesised that variation at the mtDNA and TFAM could regulate the risk of developing atherosclerosis and suffering ischemic associated episodes. Therefore, we analyzed the association between mtDNA and TFAM variants and early onset myocardial infarction.
Methods.

Patients and controls.
The study had two phases: in a first set of patients and controls (the index cohort; recruited in the period 1996-2001) we determined the association between early onset myocardial infarction (EOMI) and mitochondrial haplogroups and TFAM variants; significant associations were replicated in a second cohort of patients and controls (recruited in the period [2001] [2002] [2003] [2004] [2005] [2006] . They were recruited for a research project to characterize the genetic variation that contributed to EOMI (Alvarez et al., 1998; Batalla et al., 2000; Gonzalez et al., 2006) .
Because <10% of the EOMI cases who attended our Cardiology Department were women, only male patients were included in the study. All them had suffered a first episode of MI, defined according to the WHO MONICA (Multinational Monitoring of trends and determinants in Cardiovascular disease) (Tunstall-Pedoe et al., 1994) . All the patients underwent coronary angiography for diagnostic purposes, and only those who had at least one atherosclerotic diseased coronary vessel (luminal narrowing > 70%) were included in the study.
Controls were hospital staff, eligible residents, and blood bank donors, and were matched with patients for age and ethnicity. None of them had episodes of cardiovascular disease. Table 1 summarizes the main characteristics of patients and controls. All the patients and controls were
Caucasians from the region of Asturias (Northern Spain; total population 1 million), and gave their informed consent to participate in the study, approved by the Ethical Committee of Hospital Central Asturias.
Definition of the analytical parameters.
Blood was obtained from the patients during hospitalization and their analytical profile was determined. Patients and controls were defined as hypertensives if they had a documented history of hypertension, were receiving antihypertensive drugs, or had a systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg. Individuals with a clinical history of diabetes mellitus, who were using antidiabetic drugs, or who had a fasting blood glucosa level >15 mmol/L in more than two determinations were considered as diabetics. Patients and controls with a clinical history of hypercholesterolaemia, who were receving lipid lowering drugs, or who had fasting total colesterol > 250 mg/dL were classified as hypercholesterolaemics. Current cigarette smokers were considered as smokers.
Haplogroups classification.
A total of 10 mtDNA SNPs were determined in all the patients and controls. Briefly, DNA was obtained from 10 ml of blood and polymerase chain reaction (PCR) amplified as reported (Huerta et al., 2005) . PCR fragments were digested with the appropriated restriction enzyme, and electrophoresed on 3% agarose gels to visualise the alleles (suppl. Fig 1) . The nine haplogroups were defined by the nucleotides at the 10 polymorphic sites (see the mitomap database for haplogroups definition; www.mitomap.org) (suppl. Table 2 ). Patients and controls who were classified as H were further subdivided into H1 and non-H1 by the allele at position 3010 (A=H1; G=non-H1) (suppl. Table 1 ).
TFAM sequence variation.
The search for DNA variants in the TFAM gene was performed in the index cohort. The seven coding exons were PCR-amplified in fragments 180 to 327 bp long with primers that matched the flanking introns (suppl. Fig 2) .
The G/C exon 1 polymorphism (rs1937; S12T) affected a site for the restriction enzyme DdeI.
This SNP was genotyped in 400 patients and 450 controls through digestion with the restriction enzyme DdeI of a PCR-fragment amplified with primers for exon 1 (suppl. table 3). After electrophoresis on 3% agarose gels, the two alleles were visualized as bands of 326 bp (allele C) and 200 + 126 bp (allele G).
Statistical analysis.
Frequencies for the non-continous variables (alleles and haplogroups) between patients and controls were compared through the χ 2 or the Fisher´s exact probability tests. Odds ratios (ORs) and their 95% confidence intervals (CIs) were also calculated. We compared each haplogroup frequency with the frequency of all other haplogroups pooled into one group (van der Walt et al., 2003; van der Walt et al., 2004; Gaweda-Walerych et al., 2008) . A p<0.05 was considered as the level of statistical significance. The Student´s t-test was used to compare the difference in means between the groups. Logistic regression was used to determine the association of haplogroup with EOMI after correcting by covariates (age, BMI, diabetes, cholesterol, hypertension). All statistical analyses were performed with the SPSS statistical package (v.11.0).
Results.
EOMI and classical risk factors.
The main characteristics of MI patients and controls are summarized in Table 1 . Early onset MI was strongly associated with male gender and cigarette smoking in our index cohort (p<0.001).
We also found significantly higher frequencies of hypertensives (p<0.001), diabetics (p=0.044), and hypercholesterolaemics (p=0.036) among the index patients.
Mt haplogroup frequencies.
Haplogroup H was significantly more frequent among the patients in the index cohort (p=0.03;
OR=1.44, 95% CI=1.03-2.02) ( Table 2 ). In the replication study, haplogroup H was also significantly more frequent among the patients (p=0.02; OR=1.58, 95% CI=1.09-2.30).
Considering the H-frequencies in the index cohort, a total of 480 patients and 480 controls should be required to reach a statistical power of 80. We pooled all the patients (n=500) and controls (n=500) and obtained a p=0.002 for H vs. non-H (OR=1.50; 95% CI=1.17-1.92), with a power (% of detecting a difference) of 89. This difference remained significant when only smoker patients (H=50%, 244/487) and controls (H=37%, 99/267) were compared (p=0.0004;
OR=1.70, 95% CI=1.25-2.31) (suppl. Table 4) . Haplogroup H also remained significantly associated after correcting for total cholesterol (p=0.022), hypertension (p=0.049), and tryglicerides (p=0.045).
We determined the frequencies of subhaplogroup H1, characterized by allele 3010A. Among H individuals, the frequency of 3010A carriers was higher in controls (32%) than in patients (29%), a non-significant difference. A total of 181 of the patients (36%) were non-H1 compared to 127 of the controls (27%). Thus, the difference in H frequency between the two groups could be mainly attributed to an excess of non-H1 among the patients (p=0.003; OR=1.50, 95%CI= 1.15-1.97).
TFAM variation.
We investigated the variation in TFAM and we found a total of four previously reported variants, two in the coding (rs1937, rs17710934) and two (rs34084383, rs41283688) in the intronic flanking sequence (table 3) . Genotype frequencies did not differ from those expected under the Hardy-Weinberg equilibrium in both, patients and controls. We did not find rare sequence variants in the patients that could explain an increased risk for EOMI. In addition, none of the four common variants was significantly associated with EOMI. We also examined the interaction between the four TFAM variants and haplogroup H on EOMI risk. Genotype and allele frequencies did not differ between patients and controls for the four polymorphisms (suppl . table   5 ). Together, these data indicated that TFAM variation did not contribute to the risk for EOMI MI in our population. However, we used SSCA and DHPLC for searching TFAM variants, two techniques with an estimated rate for false negatives of approximately 5%. We cannot thus exclude that some TFAM variants were not detected in our patients/controls.
Discussion.
We found a significantly higher frequency of mitochondrial haplogroup H among EOMI patients.
This haplogroup was previously associated with some traits. For instance, riboflavin was more effective in non-H patients with migraine, and effect that could result from an increased activity of complex I (the main target of riboflavin) among H individuals (Di Lorenzo et al., 2009) .
Haplogroup H was also associated (p=0.007) with increased lipoatrophy among AIDS patients receiving nucleoside reverse transcriptase inhibitors (Hendrickson et al., 2009 ). This haplogroup has been linked to an increased survival after sepsis (Baudouin et al., 2005) . This advantage could be partly explained by the fact that H-individuals had higher maximum temperatures, being fever a basic mechanism to combat infection. A higher resistance to infections compared to other haplogroups could also explain why H is the most common European haplogroup in spite of being the most recent (Herrnstadt et al., 2004) . Haplogroup H was defined by a SNP at position 7028, a synonymous change in the cytochrome c oxidase subunit I (COI) of the mitochondrial complex IV. To define the mtDNA functional variants that could explain its association to EOMI and the other traits would require the sequencing of the whole mtDNA in H-patients.
Higher ROS production among haplogroup H cells could result in an increased endothelial dysfunction, predisposing to the development of atherosclerotic lesions in response to injuries such as compounds from cigarette smoke (Miro et al., 1999; Ballinger et al., 2002; Masayesva et al., 2006) . Martinez-Redondo et al. reported higher maximum oxygen compsumption (VO 2max) in response to exercise among H-individuals (Martinez-Redondo et al., 2010) . A positive correlation of H with electron transport chain coupling and increased ATP and ROS production was supported by the finding of higher intracellular ATP concentrations in Huntington´s disease patients carrying the 7028C allele (Arning et al., 2010) . However, at least one study did not find functionally-important bioenergetic differences between mitochondria bearing H and other haplogroups (Amo et al., 2008) .
The association between mtDNA variants and ischemic diseases has been previously studied by others (Abu-Amero et al., 2009; Nishigaki et al., 2007; Benn et al., 2008; Rosa et al., 2008; Kofler et al., 2009 ). Rosa et al. reported a higher frequency of 7028C among Portuguese patients with ischemic stroke vs. controls (Rosa et al., 2008) . This was in agreement with the significant association between haplogroup H and EOMI. Kofler et al. found a higher frequency of haplogroup T among coronary artery disease patients from Austria (Kofler et al., 2009 ). We did not find this difference, although we had reported a significant association between haplogroup T and cardiac hypertrophy ). An association of mtDNA variation with MI was also reported among Japanese, a population with a different haplogroups structure (Nishigaki et al., 2007) .
A recent study by Benn et al. did not support an association of mitochondrial haplogroups with risk of ischemic cardiovascular disease among Danish (Benn et al., 2008 ). The frequency of haplogroup H was 45.9%, and hazard ratios for hospitalization due to all cardiovascular disorders, ischemic heart disease, ischemic cerebrovascular disease, and death from all causes did not differ between the haplogroups. The difference remained non-significant after stratification by major causes of cardiovascular disease. An explanation for these discrepancies between studies is that they were based on populations from different regions, and there is a heterogenous geographical distribution of mtDNA haplogroups. Therefore, our study on a region from Spain region cannot be directly compared with other Northern European populations.
Our work has several limitations. It was based on patients with early onset myocardial infarction, a group in which genetic predisposing factors should be more relevant (compared to elderly patients) (Kathiresan et al., 2009 ). It was also based on only male patients who survived a first MI episode, and we could thus not exclude an association with MI in women or with fatal MI.
Also, we included only patients <55 years, were smokers, and had atherosclerotic diseased vessels. Other studies included also women and individuals >55 years, <50% were smokers, and the presence of angiographicaly documented CAD (stenosis >50% in at least one coronary vessel) was not an inclusion criteria. A significant proportion of our controls were recruited through a blood bank, that could result in a bias toward healthier individuals (compared to controls recruited from the general population). The frequency of diabetics, hypertesnsives, and hypercholesterolaemics could thus be underestimated in our controls. However, we think this would not affect the results because the frequency of diabetics, hypercholesterolaemics, and hypertensives among these controls were almost identical to the reported prevalence of these manifestations in the general population from Spain (Valdes et al., 2007) . In addition, haplogroup frequencies did not differ between the main clinical subgroups in patients and controls.
Finally, we searched for DNA variants in the TFAM gene in our patients and controls. TFAM is a nuclear gene that encodes the mitochondrial transcription factor, and TFAM functional variants could result in differences in mtDNA transcription and replication, two processes that have been found altered in several diseases. In addition, some TFAM polymorphisms have been linked to the risk of developing Alzheimer´s and Parkinson´s, two diseases in which mitochondrial dysfunction plays a major role Belin et al. 2007; Gaweda-Walerych et al. 2010] . We only found four common TFAM variants, with allele and genotype frequencies that did not differ between patients and controls. In addition, these frequencies did not differ between patients and controls who were haplogroup H and non-H in both, patients and controls .
Together, these data suggested that TFAM variation did not contribute to the risk for EOMI in our population.
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